摘要
目的评价以CTN-1株毒种在Vero细胞上生产的无佐剂狂犬病疫苗(冻干型)及以aG株毒种在原代地鼠肾细胞上生产的无佐剂狂犬病疫苗(液体型)的免疫效果。方法选取35名(1组)和46名(2组)一般的Ⅱ级暴露后患者,按0、3、7、14和28d的免疫程序,分别接种武汉生物制品研究所(CTN-1株毒种、Vero细胞)和河南普新生物技术公司生产的无佐剂狂犬病疫苗(aG株毒种、原代地鼠肾细胞),观察接种后的不良反应,采用快速荧光灶抑制实验(RFFTT)检测初免后7、14d血清狂犬病毒中和抗体。结果两种疫苗初免后7d的抗体阳转率分别为58.52%和65.22%,无显著性差异,初免后14d的抗体阳转率均为100%,接种Vero细胞狂苗组无不良反应;接种原代地鼠肾细胞狂苗组有1人接种第二针后出现4cm×4cm的红肿。结论两种无佐剂国产狂犬病疫苗产生保护性抗体时间短,以CTN-1株毒种在Vero细胞上生产的无佐剂狂犬病疫苗(冻干型)免疫效果好于以aG株毒种在原代地鼠肾细胞上生产的无佐剂狂犬病疫苗(液体型)。
Objective The present study was designed to evaluate CTN-1 Rabies vaccine purified by vero cell rabies vaccine （freeze-dried） and aG strain Rabies vaccine prepared by Primary Hamster Kidney Cells （liquid） , beth of which were Adjuvant-free, for their immune effects. Methods Patients with WHO category Ⅱ exposure were divided into 2 groups,35 Patients in group 1 , immunized with CTN-1 （Vero cell）Rabies Vaccine manufactured by Wuhan Institute of biological products, the other 46 in group 2 were inoculated by aG strain Rabies vaccine（PHKC） produced in Henan Puxin Biotech Co. , Ltd. The post-exposure immunizations were given on days 0, 3rd, 7th, 14th and 28th to these two groups, observation on adverse reaction was carried out after immunization, Serum samples were collected and rabies virus neutralizing antibody （RVNA） titers were tested by rapid fluorescent focus inhibition test （RFFIT） at 7 and 14 days after the primary immunization. Results Seroconversion rate in group 1 and 2 were 58. 52% and 65.22% respectively at 7 days after the first immunization, there was no significant difference between the two groups as far as immune effects were concerned, and both groups had a positive seroconversion rate of 100% on the 14th day; No abnormal reaction was found in CTN-1 groups,only one person in aG group had a 4×4 sized red swelling after the second inoculation. Conclusion These two kinds of domestically produced adjuvant-free rabies vaccine can beth elicit protection antibodies efficiently , and the CTN-1 rabies vaccine （Vero cell, freeze-dried） provided more effective and specific immune protection than aG strain vaccine（ PHKC, hquid）.
出处
《公共卫生与预防医学》
2007年第3期36-38,共3页
Journal of Public Health and Preventive Medicine
作者简介
赵德峰（1964-），男，副主任医师，主要从事传染病预防与控制工作
